The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates

Seminars in Nuclear Medicine

Volumn 31, Issue 1, 2001, Pages 62-68

  Hamdy, Neveen A T ^a   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ESTRAMUSTINE PHOSPHATE; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RADIOISOTOPE; STRONTIUM 89;

ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HORMONAL THERAPY; HUMAN; OSTEOLYSIS; PROSTATE CANCER; TREATMENT FAILURE;

EID: 0035176708     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.18767     Document Type: Article

References (76)

1. Endocrine treatment of prostate cancer
2. Hormone therapy for patients with prostate carcinoma
3. External beam radiotherapy for palliation of pain for metastatic carcinoma of the prostate
4. Half and total body radiation for carcinoma of the prostate
5. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors
6. The palliation of symptomatic osseous metastases
7. Pain management in the patients with prostate cancer
8. Malignant bone pain: Pathophysiology and treatment
9. Unsealed source therapy of painful bone metastases: An update
10. 89Sr-chloride) in patients with prostate cancer metastatic to bone
11. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases
12. Selective accumulation of strontium-89 in metastatic deposits in bone: Radiohistologic correlation
13. Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases
14. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine-resistant metastatic prostate cancer
15. Strontium-89 therapy for the palliation of pain due to osseous metastases
16. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate
17. Palliation of bone metastases in prostate cancer: Hemibody irradiation or Strontium-89?
18. Radionuclide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy
19. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89
20. Strontium-89 (Sr-89 Metastron®) and estramustine (EM) in hormone refractory prostate cancer (HRPC): A phase II study
21. Strontium-89, estramustine and vinblastine (SEV) in hormone refractory prostate carcinoma (HRPC): Concurrent chemoradiotherapy
22. RE-186 (Sn) HEDP for treatment of painful osseous metastases: Initial experience in 20 patients with hormone-resistant prostate cancer
23. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain
24. Samarium Sm-153 Lexidronam for the palliation of bone pain associated with metastases
25. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-b,g-dichloromethylene) triphosphate, by mammalian cells in vitro
26. The pharmacology of bisphosphonates and new insights into their mechanism of action
27. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-transnational prenylation of GTP-binding proteins including Ras
28. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
29. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo
30. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
31. Mechanism of action of alendronate: Geranylgeraniol, an intermediate of the mevalonate pathway prevents inhibition of osteoclast formation, bone resorption and kinase activity in vitro
32. Mechanisms of bone metastasis
33. The distribution of secondary growths in cancer of the breast
34. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis
35. Breast cancer cells interact with osteoblasts to support osteoclast formation
36. Osteoblastic metastasis in advanced prostate cancer
37. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases
38. Mechanisms of the development of osteoblastic metastases
39. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies
40. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
41. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade
42. Endothelium-derived factors as paracrine mediators of prostate cancer progression
43. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia
44. Generalized increase in bone resorption in carcinoma of the prostate
45. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption
46. Morphometric evidence for bone resorption and replacement in prostate cancer
47. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double blind randomized placebo-controlled study
48. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer
49. Correlation between bone metabolic markers and bone scan in prostatic cancer
50. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
51. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
52. Bisphosphonates in the management of prostatic carcinoma metastatic to the skeleton
53. Bisphosphonates and breast carcinoma
54. Bisphosphonates in multiple myeloma
55. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
56. Treatment of painful prostatic bone metastases with oral etidronate disodium
57. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double blind, placebo-controlled study
58. Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton
59. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma
60. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate
61. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer
62. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer
63. Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma
64. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases
65. Morphometric evidence for bone resorption and replacement in prostate cancer
66. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer
67. Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer
68. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
69. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
70. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
71. No reduction of bone metastases with adjuvant clodronate treatment in node positive breast cancer patients
72. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
73. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
74. Bisphosphonares inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
75. MMP inhibition and down regulation by bisphosphonates
76. The role of positron emission tomography in the management of bone metastases